Analyzing Time to Developing Castration-Resistant Prostate Cancer and Overall Survival after Initiating Androgen Deprivation Therapy (ADT)
There are different methods of performing ADT; these methods include continuous or intermittent as well as differences in the actual blockade itself. Understanding the superior schedule as well as the superior combination of drugs can [...]
There is Some Cross Resistance Developed Between Both the First Use of Zytiga and the First Use of Xtandi
On March 4, 2014 I wrote a post “Castrate Resistant Prostate Cancer- What to Do Next” (www.advancedprostatecancer.net/?p=4425). The basic theme of the post was about how difficult it is to know how to sequence the [...]
Finding Important Bio-Markers for Approved and Failed Drugs – Efficacy Improved and An Extended Life Rolled Up In One
Satraplatin is an oral platinum drug that is believed to bind the DNA of the cancer cell, which then prevents the cancer from being able to reproduce. Satraplatin had been tested in a phase III [...]
Castrate Resistant Prostate Cancer- What To Do Next?
Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision [...]
Prepare to Hear More About Combidex Technology
It has been announced by the International Strategic Cancer Alliance that a Dutch university that intends to launch global trials has purchased the Combidex technology. Combidex is a scan contrast that periodically gets discussed among [...]
Inflammation Negatively Impacts Overall Survival of Men with Advanced Prostate Cancer
The commonly used serum (blood) marker for inflammation is C-reactive protein (CRP). It is believed that CRP has a prognostic impact for men with metastatic prostate cancer (MPC) (advanced prostate cancer). The researchers conducted a [...]